| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1092249054 |
| P356 | DOI | 10.1186/S13045-017-0533-9 |
| P932 | PMC publication ID | 5646121 |
| P698 | PubMed publication ID | 29041946 |
| P50 | author | Michael Fichtner | Q57421969 |
| Martin Trepel | Q88340222 | ||
| P2093 | author name string | Martin Dreyling | |
| Mascha Binder | |||
| P2860 | cites work | Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network | Q44135718 |
| Cyclin D1-negative mantle cell lymphoma | Q44179538 | ||
| Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity | Q45141844 | ||
| Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur | Q45182734 | ||
| Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res | Q45236772 | ||
| Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. | Q47736956 | ||
| Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals | Q48074034 | ||
| Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q50205176 | ||
| Molecular components of the B-cell antigen receptor complex of the IgM class | Q50335807 | ||
| Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence. | Q51027142 | ||
| Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. | Q52013904 | ||
| Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. | Q52940574 | ||
| Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. | Q52947124 | ||
| Bendamustine-rituximab in mantle cell lymphoma. | Q52947485 | ||
| Molecular evidence for antigen drive in the natural history of mantle cell lymphoma. | Q52953600 | ||
| Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. | Q53029323 | ||
| Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. | Q53129637 | ||
| Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression | Q57580345 | ||
| Genomic and epigenomic co-evolution in follicular lymphomas | Q60345277 | ||
| Immunoglobulin genes | Q70520549 | ||
| BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases | Q71121151 | ||
| Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma | Q73062541 | ||
| Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma | Q73307419 | ||
| Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling | Q83587583 | ||
| Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor | Q24597028 | ||
| Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia | Q24599100 | ||
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity | Q24656700 | ||
| Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a Staphylococcal Toxin | Q24673297 | ||
| Targeting the B-cell receptor signaling pathway in B lymphoid malignancies | Q26828782 | ||
| Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins | Q27635202 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| Innate immune recognition | Q27860721 | ||
| Staphylococcus aureus infections | Q28131787 | ||
| A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project | Q28239256 | ||
| A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma | Q28254924 | ||
| Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling | Q28272891 | ||
| Aggressive lymphomas | Q28279743 | ||
| Virus-encoded superantigens | Q28776748 | ||
| Somatic generation of antibody diversity | Q29616439 | ||
| Predominant autoantibody production by early human B cell precursors | Q29619656 | ||
| Postibrutinib outcomes in patients with mantle cell lymphoma | Q30277756 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations | Q30496575 | ||
| Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells | Q30994095 | ||
| Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients | Q33333989 | ||
| The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells | Q33585273 | ||
| Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity | Q33771413 | ||
| Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. | Q33835200 | ||
| Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin | Q33849548 | ||
| Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia | Q33873337 | ||
| Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. | Q33873343 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
| Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | Q34001339 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| Do mantle cell lymphomas have an 'Achilles heel'? | Q34090009 | ||
| Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen | Q34150551 | ||
| Pathology of B-cell lymphomas: diagnosis and biomarker discovery | Q38345563 | ||
| Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma | Q38373698 | ||
| Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management | Q38535489 | ||
| B-cell receptor signaling in the pathogenesis of lymphoid malignancies | Q38557936 | ||
| Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study | Q38670952 | ||
| Targeting of B-cell receptor signalling in B-cell malignancies. | Q38744922 | ||
| Analysis of the IGHV region in Burkitt's lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis | Q39028931 | ||
| Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma | Q39040982 | ||
| Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis | Q39107651 | ||
| A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies | Q40020213 | ||
| Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia | Q40163057 | ||
| Cross talk between immunoglobulin heavy-chain transcription and RNA surveillance during B cell development. | Q40314484 | ||
| Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma | Q40330626 | ||
| Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymp | Q40696072 | ||
| Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. | Q40716705 | ||
| Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network | Q40880831 | ||
| Structures of bacterial immunoglobulin-binding domains and their complexes with immunoglobulins | Q40927379 | ||
| Clonal selection and learning in the antibody system | Q41002744 | ||
| Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma | Q42384350 | ||
| Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling | Q42503470 | ||
| Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases | Q42610807 | ||
| Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma | Q43948770 | ||
| CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. | Q44099314 | ||
| Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins | Q34276522 | ||
| Antigen receptors on B lymphocytes | Q34420640 | ||
| IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma | Q34440364 | ||
| The evolution of adaptive immune systems | Q34497263 | ||
| Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma | Q34619308 | ||
| A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). | Q34663617 | ||
| Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia | Q35642807 | ||
| Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma | Q35786734 | ||
| Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling | Q35848185 | ||
| Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma | Q35848973 | ||
| Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies | Q36083000 | ||
| Mechanisms of B-cell lymphoma pathogenesis | Q36085626 | ||
| Does DNA repair occur during somatic hypermutation? | Q36173864 | ||
| Molecular pathogenesis of mantle cell lymphoma | Q36290246 | ||
| Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells | Q36369816 | ||
| Confounding B-cell defences: lessons from a staphylococcal superantigen | Q36488759 | ||
| Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 | ||
| CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma | Q36628297 | ||
| Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature | Q36629194 | ||
| The SYK tyrosine kinase: a crucial player in diverse biological functions | Q36662082 | ||
| Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen | Q36788328 | ||
| The cellular origin of mantle cell lymphoma. | Q36851684 | ||
| The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Q36920426 | ||
| Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation | Q36972595 | ||
| Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma | Q37076425 | ||
| Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features | Q37149519 | ||
| Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus | Q37322841 | ||
| Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia | Q37421797 | ||
| Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma | Q37534547 | ||
| Structure and function of immunoglobulins | Q37696721 | ||
| Pathogenesis of non-Hodgkin's lymphoma | Q37863998 | ||
| Targeting Bruton's tyrosine kinase in B cell malignancies | Q38198490 | ||
| Staphylococcal protein A induces biased production of Ig by VH3-expressing B lymphocytes. | Q38303556 | ||
| Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. | Q38306094 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood proteins | Q425056 |
| cell surface receptor | Q2476074 | ||
| mantle cell lymphoma | Q268713 | ||
| globulins | Q321710 | ||
| membrane protein | Q423042 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 164 | |
| P577 | publication date | 2017-10-17 | |
| P1433 | published in | Journal of Hematology & Oncology | Q15724593 |
| P1476 | title | The role of B cell antigen receptors in mantle cell lymphoma | |
| P478 | volume | 10 |
| Q58773255 | Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma |
| Q89998321 | Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma |
| Q61797408 | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
| Q50350976 | Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies. |
Search more.